Knight Therapeutics, Inc. · TSX:GUD
Knight Therapeutics — Investor Presentation (October 2024)
20 slides from Knight Therapeutics's investor presentation, October 2024
Slide 1: Knight Therapeutics Inc. (TSX: GUD) Investor Presentation
Building a leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) Investor presentation 1 October 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated
Slide 3: Knight Overview
Knight Overview Knight is a multinational specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canada and Latin America • Since founding in February 2014 – Raised $685M at increasing valuations ($3.50 - $10.00) – Deployed or committed to deploy
Slide 4: Knight's Evolution
Knight’s Evolution 2011-2012 2013-2014 2015 2017 2019-2024 5 7 9 10 11 countries countries countries countries countries • Emerging specialty • Acquisition of • Expanded further • Moved HQ to • Acquisition of GBT player in the United Medical geographical Montevideo coverage (Bolivia and • Acquisitio
Slide 5: Our Footprint
Our Footprint Revenue by Geography1 ∼ $350M in Revenue1 11 Countries + distributors in Central America and Caribbean ∼750 Employees +100 Products Headcount by Geography2 18 Pipeline Products +20 Partners Knight Affiliates Knight Distributors 3 Manufacturing Plants 1 R&D Center 1 Regional Distributio
Slide 6: Our Growth Strategies
Our Growth Strategies 1 In-license late-stage prescription pharmaceuticals Product 2 Acquire mature or “under-promoted” products from Big Pharma Portfolio 3 Develop near-term, low risk / low expense products Knight’s involvement Regulatory Market Sales and Discovery Pre-Clinical Clinical Trials Appr
Slide 7: Our Market / Product Portfolio
Our Market Pan-American (ex US) market represents ~6% of global pharmaceutical market Product Portfolio *Source: Local IQVIA Audits MAT Feb 2023, except for (*) MATJAN for Non-retail ARG, MATDEC for Non-retail CEA and MATSEP for Non-retail COL. Considered only retail for COL ** Exchange rates – coun
Slide 8: Our Portfolio
Our Portfolio KEY PRODUCTS PRODUCT PORTFOLIO1 Oncology and Hematology Infectious Diseases REVENUE BY THERAPEUTIC AREA1 Neurology and Specialty IPX203 1 Trailing twelve months ended June 30, 2024, excluding impact of hyperinflation 8
Slide 9: Pipeline and Products in Early Launch Stage
Pipeline and Products in Early Launch Stage Building for long-term growth over $150M peak potential sales TERRITORY LAUNCH / EXPECTED PRODUCT CA BR AR CO MX LAUNCH YEAR Oncology/Hematology Minjuvi® (tafasitamab) N/A2 Q1-24 Submitted Submitted Submitted 2024-2026 Pemigatinib N/A2 Submitted Submitted
Slide 10: Our Partners
. Our Partners AstraZeneca? (4 GILEAD lh Bristol Myers Squibb LL. GB onsir le NSHORE TherapeuticsMD a ELSI N. N (basilea) @- Debiopharm PHARMACEUTICA ge, O @Sup pernus’ rigel te mneal WKnight 10
Slide 11: Strategic Fund Investments
Strategic Fund Investments 1 Fund investments • Invested to obtain preferential access to innovative products for Canadian market • Financial returns have been attractive, but have not been as effective at generating product leads • No longer investing into funds, beyond already committed capital4 F
Slide 12: Financial Highlights: Key Promoted Products Driving Growth
Financial Highlights Key Promoted Products Driving Growth Knight acquires Biotoscana end of 2019 Note: Revenues exclude impact of hyperinflation/IAS 29 12
Slide 13: Financial Highlights: Strong EBITDA and Operating Cash Flows
Financial Highlights Strong EBITDA and Operating Cash flows Knight acquires Biotoscana end of 2019 Note: Adjusted EBITDA is a non-GAAP measure and defined as operating income or loss adjusted to exclude amortization and depreciation, impairment of non- current assets, purchase price allocation accou
Slide 14: Capital Allocation
Capital Allocation Over $240M invested in NCIB or 30% of shares outstanding* Knight acquires Biotoscana end of 2019 *Since inception of NCIB, average buy back price at $5.70 14
Slide 15: Financial Highlights
Financial Highlights Income Statement Highlights – TTM June 30, 2024 Revenue $350.0 million $3.45/share Adjusted EBITDA $56.9 million $0.56/share Balance Sheet Highlights – June 30, 2024 Cash and Marketable Securities $152.7 million $1.51/share Bank Loans $51.0 million $0.50/share Financial Assets1
Slide 16: Management Team
Management Team Monica Percario - Brazil Global VP Regulatory and Quality Sanofi, Head of Regulatory and Center of Expertise LATAM Samira Sakhia - Canada Farmasa (now Hypera Pharma), Regulatory Affairs President and Chief Executive Officer Extensive experience with >70 products approved across LATAM
Slide 17: Board of Directors
Board of Directors Jonathan Ross Goodman Robert N. Lande Executive Chairman Paladin Labs, Board member from 1995 to 2014 Knight Therapeutics, Founder FXCM Group LLC, President Paladin Labs, Co-founder, former President & CEO Michael J. Tremblay Former President of Astellas Canada James C. Gale Forme
Slide 18: Key Achievements - last 12 months
Key Achievements - last 12 months Period Key Achievements Q2-24 Entered into exclusive supply and distribution agreement for Jornay PMTM for Canada and Latin America. Q1-24 In-licensed IPX203 (carbidopa and levodopa extended-release capsules) for Canada and Latin America Submitted fostamatinib
Slide 19: Why Knight – Great value in growing markets
Why Knight – Great value in growing markets Unique Platform in high growth Profitable Business with strong Revenues, Adj. EBITDA and Cashflow Strong Financial Foundation markets TTM Revenues TTM Adj. EBITDA +7% vs PY ~3% vs PY Experienced Management Team Expanding Pipeline Strong Proven Track Record
Slide 20: Knight Therapeutics Inc. (TSX: GUD)
Building a leading specialty pharmaceutical company Knight Therapeutics Inc. (TSX: GUD) Investor presentation 20 October 2024
Knight Therapeutics — Investor Presentation (October 2024) on 6ix